论文部分内容阅读
BRL17421〔6β-(2-羧基-2-噻吩-3-乙酰胺基)-6a-甲氧青霉烷酸二钠盐〕是种新的抗菌谱极广的半合成β-内酰胺抗生素,对很多典型的革兰氏阴性、革兰氏阳性细菌有作用,最小抑菌浓度为1.0～5.0微克/毫升。但是,BRL17421对绿脓杆菌及脆弱拟杆菌的抗菌活性要比对肠杆菌科菌株小得多。大多数所试验的绿脓杆菌对BRL17421的敏感性要比羧噻吩青霉素小5～20倍。然而,那些产生大量质粒中介(plasmid-mcdiated)β-内酰胺酶的、对羧噻吩青霉素呈高度耐药的菌株,对BRL17421的敏感性与典
BRL17421 [6β- (2-carboxy-2-thiophene-3-acetamido) -6a-methoxy penicillanate disodium salt] is a new antibiotic spectrum of very broad semi-synthetic β-lactam antibiotics, Many typical Gram-negative, Gram-positive bacteria have a role, the minimum inhibitory concentration of 1.0 to 5.0 micrograms / milliliter. However, BRL17421 has a much lower antibacterial activity against Pseudomonas aeruginosa and Bacteroides fragilis than against Enterobacteriaceae. Most of the tested Pseudomonas aeruginosa to BRL17421 sensitivity than carboxymethyl thiophene penicillin 5 to 20 times smaller. However, the susceptibility of BRL17421 to those strains that are highly resistant to cefotaxime that produce a large number of plasmid-mcdiated β-lactamases,